Billing and Coding: MolDX: Phenotypic Biomarker Detection from Circulating Tumor Cells

The Biocept Target Selector HER2 Assay and AR-V7 protein test from circulating tumor cells is considered reasonable and necessary under MolDX LCD L38678 and should be reported with CPT 81479. Claims must include 1 unit of service, the appropriate DEX Z-Code adjacent to the CPT code using the specified Part A/Part B fields (Loop 2400/SV101-7/Box 19 for Part B; SV202-7/Block 80 for Part A), and the applicable ICD-10-CM diagnosis code(s).

"Biocept Target Selector HER2 Assay and Androgen Receptor Variant (AR-V7) Protein Test for phenotypic biomarker detection from circulating tumor cells is considered reasonable and necessary per MolD..."

Sign up to see full coverage criteria, indications, and limitations.